Dosimetry and Therapeutic Ratios for Rhenium-186 HEDP
Open Access
- 11 April 2013
- journal article
- research article
- Published by Wiley in ISRN Molecular Imaging
- Vol. 2013, 1-6
Abstract
Rhenium-186 (Re-186) is a β-emitting radionuclide. Emitted β-particles have ranges up to 4.5 mm in tissue, capable of delivering high doses to skeletal regions of high Re-186 concentrations while sparing adjacent radiosensitive regions and thus making the irradiation well tolerated for the patient. Along with the β-emissions, γ-rays are emitted having an adequate energy for imaging during therapy and biodistribution assessment for patient-specific dosimetry calculations. The relatively short physical half-life combined with the β-emissions allows the delivery of relatively high activity rate for a short period of time in areas of concentration. This study is a short review concerning the palliative treatment of skeletal metastases using 186Re-HEDP. After presenting the dominant ways of 186Re production, special emphasis is given to dosimetry issues while the effect of palliation therapy can be evaluated through the comparison of the absorbed dose in metastatic lesion relatively to the normal bone region. Accurate dose estimation is required taking into account the anatomic individual difference of each patient. For this purpose a patient specific dosimetric model considering metastatic lesions as spherical nodules is introduced. In order to quantify in a representative way the results of palliation treatment, the concept of therapeutic ratios is analyzed.Keywords
This publication has 19 references indexed in Scilit:
- Management of Metastatic Bone Pain with Repeated Doses of Rhenium 186-HEDP in Patients Under Therapy with Zoledronic Acid: A Safe and Additively Effective PracticeCancer Biotherapy and Radiopharmaceuticals, 2009
- Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- EANM procedure guideline for treatment of refractory metastatic bone painEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesinNuclear Medicine and Biology, 2006
- Feasibility of 186 Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancerJournal of Cancer Research and Clinical Oncology, 2003
- A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patientsBreast Cancer Research and Treatment, 2001
- Production method of no-carrier-added186ReJournal of Radioanalytical and Nuclear Chemistry, 1996
- Reactor production and processing of therapeutic radioisotopes for applications in nuclear medicineJournal of Radioanalytical and Nuclear Chemistry, 1996
- Safety and Efficacy of Repeated Sequential Administrations of Re-186(Sn)HEDP as Palliative Therapy for Painful Skeletal MetastasesClinical Nuclear Medicine, 1992